Armen Shanafelt brings over 29 years of operational experience in the pharmaceutical, biotechnology, and diagnostic businesses to Lilly Ventures. Previous to joining Lilly Ventures in 2009, Armen held leadership and executive positions in the R&D organizations of DNAX Research Institute, Bayer Pharmaceuticals, Roche Diagnostics, and Eli Lilly and Company.
Armen currently serves as a director on the boards of Aeglea BioTherapeutics (NASDAQ: AGLE), Aileron Therapeutics (NASDAQ: ALRN), Protagonist Therapeutics (NASDAQ: PTGX), Surface Oncology (NASDAQ: SURF), Sutro Biopharma and Symic Biomedical. He is a Kauffman Fellow (Class 14).
Armen received his B.S. Degree in Chemistry and Physics from Pacific Lutheran University, and his Ph.D. in Chemistry from the University of California, Berkeley.